Skip to main content
Premium Trial:

Request an Annual Quote

KellBenz Licenses Antibodies from AdnaGen

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KellBenx has licensed antibodies from AdnaGen which it will use to develop non-invasive prenatal diagnostics, AdnaGen's parent company, OncoVista Innovative Therapies said today.

Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders," OncoVista said in a statement.

FNRBCs have been identified in maternal blood as a possible source for monitoring and diagnosing maternal, fetal, and neonatal health and disease.

KellBenz has exclusive worldwide rights to commercialize AdnaGen's antibodies, called monoclonal antibodies with specificity for fetal erythroid cells, OncoVista said.

Financial terms were not disclosed.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.